试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Idogen AB
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer.CTIS2023-504514-29-00Astellas Pharma Global Development Inc.240
招募中
1 期
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functioCTIS2022-500774-34-00Biohorm S.L.44
招募中
1 期
First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphomaymphoma, Solid tumorMedDRA version: 20.0Level: HLGTClassification code: 10025323Term: Lymphomas NEC Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2023-509532-25-00eukos Biotech S.L.42
进行中（未招募）
1 期
First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor ß in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])Metabolic dysfunction-associated steatotic liver disease, Crohn’s disease, Primary Sclerosing CholangitisMedDRA version: 24.1Level: LLTClassification code: 10086076Term: Fibrostenotic Crohn´s disease Class: 100000004848MedDRA version: 20.0Level: PTClassification code: 10076331Term: Steatohepatitis Class: 100000004871MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-506555-15-00Antaros Medical AB30
进行中（未招募）
1 期
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.Hereditary angioedema (HAE)MedDRA version: 23.1Level: PTClassification code: 10019860Term: Hereditary angioedema Class: 100000004850CTIS2024-511196-15-00Pharvaris Netherlands B.V.14